Drug intelligence / Profile preview

[161Tb]Tb-PSMA-I&T

Development stage: Phase 2
Lead developer: Peter MacCallum Cancer Centre
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

[161Tb]Tb-PSMA-I&T is a radioligand therapy that combines the radionuclide Terbium-161 with a PSMA-targeting molecule (PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It works by delivering targeted radiation to PSMA-positive cancer cells. Terbium-161 emits both beta particles and abundant Auger electrons, which potentially provides enhanced therapeutic efficacy compared to established Lutetium-177-based PSMA therapies, particularly for micrometastases and single tumor cells. The Auger electrons deposit a higher concentration of radiation over a shorter path length, which may be more effective for treating small metastatic deposits.

Brand names: PSMA I&T-β
Other names: [161Tb]Tb-PSMA-I&T

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on [161Tb]Tb-PSMA-I&T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [161Tb]Tb-PSMA-I&T.

Explore the full profile